J. Goldman & Co’s Kura Oncology KURA Stock Holding History

J. Goldman & Co’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-54,000	Closed	-$660K	–	443
2023 Q1	$660K	Buy	+54,000	New	+$674K	0.03%	252

Other funds holding KURA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

J. Goldman & Co's KURA Position: Q4 2024 in Review

J. Goldman & Co sold out of Kura Oncology (KURA) in Q4 2024, closing a stake of 31,654 shares — an estimated $619K sold.

J. Goldman & Co first reported a position in KURA in Q2 2020 and held it in 4 quarters. The position peaked at $853K in Q2 2020. 185 funds tracked by Wall St. Rank hold KURA as of Q4 2024.

J. Goldman & Co reported no remaining Kura Oncology position as of Q4 2024 after selling out during the quarter.
J. Goldman & Co sold 31,654 Kura Oncology shares in Q4 2024, an estimated $619K.
J. Goldman & Co first reported a position in Kura Oncology in Q2 2020 and held it in 4 quarters.
J. Goldman & Co's Kura Oncology position peaked at $853K in Q2 2020.
185 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2024.

Based on J. Goldman & Co's 13F filing for Q4 2024, filed 14 Feb 2025.